Sophia Varadkar

Sophia Varadkar

Auto-generated profile, based on publicly available information

Sophia Varadkar

Department of Neurology, Great Ormond Street Hospital for children, London, United Kingdom; Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, UCL, London United Kingdom

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in The Lancet Neurology
Verified
Journal Article
Closed access
SVSophia Varadkar
Sophia Varadkar
CBChristian G Bien
Christian G Bien
CKCarol A Kruse
Carol A Kruse
FJFrances E Jensen
Frances E Jensen
JBJan Bauer
Jan Bauer
JCJ Helen Cross
J Helen Cross

15 June 2020 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
AVAikaterini Vezyroglou
Aikaterini Vezyroglou
SVSophia Varadkar
Sophia Varadkar
TBThomas Bast
Thomas Bast
EHEdouard Hirsch
Edouard Hirsch
KSKarl Strobl
Karl Strobl
JCJ Helen Cross
J Helen Cross
Variants in the gene SCN1A are a common genetic cause for a wide range of epilepsy phenotypes ranging from febrile seizures to Dravet syndrome. Focal onset seizures and structural lesions can be present in these patients and the question arises whether epilepsy surgery should be considered. We report eight patients (mean age 13y 11mo [SD 8y 1mo], range 3–26y; four females, four males) with SCN1A variants, who underwent epilepsy surgery. Outcomes were variable and seemed to be directly related to the patient’s anatomo‐electroclinical epilepsy phenotype. Patients with Dravet syndrome had unfavourable outcomes, whilst patients with focal epilepsy, proven to arise from a single structural lesion, had good results. We conclude that the value of epilepsy surgery in patients with an SCN1A variant rests on two issues: understanding whether the variant is pathogenic and the patient’s anatomo‐electroclinical phenotype. Careful evaluation of epilepsy phenotype integrated with understanding the significance of genetic variants is essential in determining a patient’s suitability for epilepsy surgery. Patients with focal onset epilepsy may benefit from epilepsy surgery, whereas those with Dravet syndrome do not.What this paper adds: Patients should not automatically be excluded from epilepsy surgery evaluation if they carry an SCN1A variant. Patients with focal epilepsy may benefit from epilepsy surgery; those with Dravet syndrome do not.

11 April 2019 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
PDF file
GBGeorgina Corbet Burcher
Georgina Corbet Burcher
HLHolan Liang
Holan Liang
RLRebecca Lancaster
Rebecca Lancaster
JCJ Helen Cross
J Helen Cross
MTMartin Tisdall
Martin Tisdall
IHIsobel Heyman
Isobel Heyman

19 June 2003 in Epilepsia
Verified
Journal Article
Open access
PDF file
SVSophia Varadkar
Sophia Varadkar
JDJohn Duncan
John Duncan
JCJ. Helen Cross
J. Helen Cross
Click on the article title to read more.

12 January 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
SPSerena Pellegrin
Serena Pellegrin
TBTorsten Baldeweg
Torsten Baldeweg
SPSuresh Pujar
Suresh Pujar
FDFelice D'Arco
Felice D'Arco
GCGaetano Cantalupo
Gaetano Cantalupo
JCJ. Helen Cross
J. Helen Cross
Objective To verify safety and efficacy of the corticosteroid-sparing drug azathioprine (AZA) in Rasmussen syndrome (RS), we retrospectively analyzed a cohort of patients with RS recruited in a single pediatric neuroscience center. Methods We compared outcomes in 30 patients with RS who received AZA with 23 patients who were not treated with this drug. We used a multimodal approach to correlate therapy with clinical features (seizures, epilepsia partialis continua [EPC], hemiparesis) and neuroimaging markers of progressive brain atrophy. Results AZA was well tolerated; only 1 patient discontinued treatment due to pancytopenia. In 27 of 30 patients receiving AZA, all of whom were corticosteroid responders, corticosteroid therapy could be weaned or reduced without worsening of seizures in 89%. Patients receiving AZA had a lower prevalence of EPC (42% vs 67% in controls) and hemiparesis (64% vs 92%, respectively). Cox regression showed for the AZA group compared to controls a delayed time to (1) EPC (≈2 years, exp[B] = 0.295, 95% confidence interval [CI] 0.108–0.807; p = 0.017), (2) hemiparesis (≈1 year, exp[B] = 0.315, 95% CI 0.137–0.724; p = 0.007), and (3) surgery (≈2 years, exp[B] = 2.068, 95% CI 1.012–4.227; p = 0.046). However, there were no group differences in cognitive decline over time (IQ change per year) or in hemispheric gray matter atrophy on serial MRI scans. Conclusion AZA treatment appears to slow clinical progression of RS in steroid responders; this will give the greatest advantage in patients in the early stages of the disease in whom surgical decision-making may require further time. Classification of Evidence This study provides Class III evidence that for pediatric patients with RS AZA is well tolerated and slows hemiparesis and appearance of EPC.

1 July 2018 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
SBSophie Bennett
Sophie Bennett
ACAnna E. Coughtrey
Anna E. Coughtrey
IHIsobel Heyman
Isobel Heyman
SGSuzanna Greally
Suzanna Greally
HCHarriet Clarkson
Harriet Clarkson
RSRoz Shafran
Roz Shafran